A process for predicting a patient's response to mesalamine for the treatment of ulcerative colitis, the process comprises the steps of: Identifying a patient diagnosed with UC; determining the location of the UC; mixing a blood sample obtained from the patient with one or more separators in a selected tube to create a first blood component, wherein the first blood component is a serum or plasma; selecting a panel, wherein the panel identifies one or more target biomarkers for the location of the UC and the gender of the patient; determining the level of each of the one or more target biomarkers in the first blood component; making a first comparison of the levels of the one or more target biomarkers in the first blood component to levels in a reference; and using the first comparison to create an outcome predicting the effectiveness of mesalamine treatment for the patient, wherein the panel selected is: (i) for male and female patients having pancolitis and extensive colitis and wherein the one or more identified target biomarkers are selected from the list consisting of GSTM1, IL13, RETN and Histone H2a autoantibody; (ii) for female left sided colitis and wherein the one or more identified target biomarkers are selected from the list consisting of antibody to L. donovani, HTCLV1/2, and HSP90alpha autoantibody; (iii) for male left sided colitis and wherein the one or more identified target biomarkers are selected from the list consisting of APOA1, PRL, HSP 71 autoantibody and IgA; (iv) for female proctosigmoiditis and wherein the one or more identified target biomarkers are selected from the list consisting of CCL22 and antibody to cholera toxin; or (v) for male proctosigmoiditis and wherein the one or more selected target biomarkers are selected from the list consisting of ILRN and CD40 LG. Identifying a patient diagnosed with UC; determining the location of the UC; mixing a blood sample obtained from the patient with one or more separators in a selected tube to create a first blood component, wherein the first blood component is a serum or plasma; selecting a panel, wherein the panel identifies one or more target biomarkers for the location of the UC and the gender of the patient; determining the level of each of the one or more target biomarkers in the first blood component; making a first comparison of the levels of the one or more target biomarkers in the first blood component to levels in a reference; and using the first comparison to create an outcome predicting the effectiveness of mesalamine treatment for the patient, wherein the panel selected is: (i) for male and female patients having pancolitis and extensive colitis and wherein the one or more identified target biomarkers are selected from the list consisting of GSTM1, IL13, RETN and Histone H2a autoantibody; (ii) for female left sided colitis and wherein the one or more identified target biomarkers are selected from the list consisting of antibody to L. donovani, HTCLV1/2, and HSP90alpha autoantibody; (iii) for male left sided colitis and wherein the one or more identified target biomarkers are selected from the list consisting of APOA1, PRL, HSP 71 autoantibody and IgA; (iv) for female proctosigmoiditis and wherein the one or more identified target biomarkers are selected from the list consisting of CCL22 and antibody to cholera toxin; or (v) for male proctosigmoiditis and wherein the one or more selected target biomarkers are selected from the list consisting of ILRN and CD40 LG. (i) for male and female patients having pancolitis and extensive colitis and wherein the one or more identified target biomarkers are selected from the list consisting of GSTM1, IL13, RETN and Histone H2a autoantibody; (ii) for female left sided colitis and wherein the one or more identified target biomarkers are selected from the list consisting of antibody to L. donovani, HTCLV1/2, and HSP90alpha autoantibody; (iii) for male left sided colitis and wherein the one or more identified target biomarkers are selected from the list consisting of APOA1, PRL, HSP 71 autoantibody and IgA; (iv) for female proctosigmoiditis and wherein the one or more identified target biomarkers are selected from the list consisting of CCL22 and antibody to cholera toxin; or (v) for male proctosigmoiditis and wherein the one or more selected target biomarkers are selected from the list consisting of ILRN and CD40 LG.